Clinical Trial Update: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating steroids and tyrosine kinase inhibitors in combination with blinatumomab or chemotherapy for newly diagnosed BCR-ABL1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia Bcr-abl1 Positive

Drugs mentioned

• Blinatumomab (blinatumomab)
• Chemotherapy (chemotherapy)
• DEXAMETHASONE (Dexamethasone)
• Tyrosine kinase inhibitors

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Status: ACTIVE_NOT_RECRUITING